Introducing SERB Pharmaceuticals

SERB Pharmaceuticals equips healthcare providers worldwide with lifesaving medicines for patients facing rare diseases and emergencies.

Healthcare providers in over 100 countries rely on us for a broad range of essential medicines delivered via healthcare systems, first responders, emergency preparedness agencies, and non-profit organisations.

Who we are

SERB began in the 1950s as Société d’Études et de Recherches Biologiques (Company for Biologic Study and Research).

For over 30 years we have consistently supplied emergency medicines, medical countermeasures, and the world’s leading portfolio of antidotes. In this time, we have built trusted partnerships, integrated infrastructure and quality processes to get our medicines to patients with urgency.

Our proven ability to acquire, develop, manufacture, launch and commercialize specialist medicines allows us to meet critical medical needs.

Improving patients’ quality of life and offering hope is what motivates and inspires us.

Learn more about SERB

70+

Medicines

500+

Dedicated employees

Direct sales in

18

countries

Supplying

100+

countries

Latest news

  • 19 May 2026
    SERB Pharmaceuticals to acquire European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma for €115 million
    19 May 2026: SERB Pharmaceuticals (“SERB”) and Hansa Biopharma AB (“Hansa”) (Nasdaq Stockholm: HNSA) today announced that they have entered into an agreement under which SERB will acquire the exclusive development and commercialisation rights to Idefirix® (imlifidase) in the European Union, United Kingdom, Switzerland, Norway, Liechtenstein, Iceland and the Middle East and North Africa (MENA) […]
    Read release
  • 07 May 2026
    SERB Pharmaceuticals Announces ThyroSafe 130mg Potassium Iodide Tablets are Now Commercially Available in the US
    SERB Pharmaceuticals, a global specialty pharmaceutical company focused on rare diseases and medical emergencies, announced that ThyroSafe potassium iodide tablets are now commercially available in a 130 mg dose.
    Read release
  • 12 January 2026
    SERB Pharmaceuticals Expands Scientific Leadership with Appointment of Dr. Peter C. Adamson to US Board 
    Boston, 12 January 2026: SERB Pharmaceuticals, a global speciality pharmaceutical company focused on rare diseases and medical emergencies, has appointed Dr Peter C. Adamson, MD, FASCO, to its US Board as a Non-Executive Director. Dr. Adamson being exceptional credentials as a globally recognized physician-scientist and leader in oncology drug development and clinical pharmacology. Dr Adamson […]
    Read release
See all news

Latest insight

  • CBRN
  • Critical Care

Soukaïna Boughaba, International Brand Manager

14 July 2025

SERB completes CBRN Video Series

Uncover the complexities of Chemical, Biological, Radiological, and Nuclear threats with our new video series: “Today’s CBRN reality”.

Read more
See all insights
You are leaving the SERB.com global corporate website
This link will take you to a third-party website, the terms of use and the privacy policy of which may be different. SERB declines all responsibility in that regard and in case of a breach of its privacy policy by the third-party website. Moreover, SERB is not responsible for any information or opinion contained in any third-party website.
Choose your region